Overview

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

Status:
Completed

Trial end date:
2017-06-02

Target enrollment:

Participant gender:

Summary

This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or every 4 weeks (Q4W) for 24 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). A safety run-in assessment will be conducted prior to initiating enrollment in the randomized study.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Immunoglobulin Fab Fragments